Xuemei Huang, M.D., Ph.D., Pennsylvania State University, University Park
This team will seek to determine whether state-of-the-art magnetic resonance imaging (MRI) scans can reveal subtle structural and chemical changes in the brain, including iron accumulation, during Parkinson's.
Vladislav Petyuk, Ph.D., Battelle Pacific Northwest Laboratories, Richland, Wash.
This group will seek to identify new components of the Lewy bodies that accumulate in the brain during Parkinson's, and then use ultra-sensitive methods to see if any of these proteins have leaked into CSF or blood.
Clemens Scherzer, M.D., Brigham and Women's Hospital, and Harvard University, Boston
This team will investigate whether Parkinson's is associated with changes in the activity of non-coding, "dark matter" genes (which do not make proteins) in brain tissue, blood and CSF. The team also will integrate the PDBP with a Parkinson's biomarkers study at the Harvard Neurodiscovery Center, which has already enrolled about 2,000 individuals.
Andrew West, Ph.D., University of Alabama at Birmingham
This team discovered that the Parkinson's-related protein LRRK2 and many other proteins can be detected in urine, within microscopic structures called exosomes; they will investigate whether exosome-related proteins can serve as biomarkers.
Jing Zhang, M.D., Ph.D., University of Washington, Seattle*
CSF appears to contain potential biomarkers, but blood is easier to obtain. Therefore, this group's strategy is to conduct an expanded search for biomarkers in CSF and then search again for the strongest candidates
|Contact: Daniel Stimson|
NIH/National Institute of Neurological Disorders and Stroke